Fertility · Advanced Maternal Age
TTC After 35: What Actually Changes, and What to Do About It
After 35, fertility doesn't fall off a cliff — but the math does change. Monthly conception odds drop from ~20% in your early 30s to ~10–15% by 37, and miscarriage risk roughly doubles between 30 and 40. The good news: most of the levers (egg quality, cycle timing, metabolic health, male factor) respond to a focused 90-day plan.
The real numbers, not the scary headlines
Popular media flattens fertility after 35 into a single cliff. The data is more nuanced. In natural-cycle studies (Dunson 2004, Rothman 2013), cumulative 12-month conception rates for regularly cycling women in monogamous, well-timed relationships are approximately 82% at ages 27–34, 74% at ages 35–39, and 55% at ages 40–44. That is a real decline — but it is a gradient, not a wall. What steepens sharply is the miscarriage curve: pregnancy loss rises from ~10% under 30 to ~20% at 35, ~30% at 40, and ~50% by 43. That climb is driven almost entirely by aneuploidy — chromosomal errors that occur during meiosis when mitochondrial energy in the egg runs low.
What actually declines, cellularly
Three biological changes drive the age curve, and they matter because the interventions map to them:
- Oocyte mitochondrial function. A mature egg holds ~100,000 mitochondria — more than any other human cell. Their job is to power the two meiotic divisions that separate chromosomes. As mitochondrial output drops with age, error rates in that separation rise. This is the substrate under age-related aneuploidy and miscarriage.
- Spindle apparatus fidelity. The microtubule machinery that pulls chromosomes apart becomes less accurate with age, partly because it depends on ATP output from those same mitochondria.
- Ovarian reserve. Total follicle count falls with age. This drives time-to-pregnancy and IVF response but does not directly cause miscarriage.
The clinical translation: mitochondrial support (CoQ10/ubiquinol), insulin sensitization (myo-inositol), and antioxidant load (ALA, omega-3 DHA, vitamin E) target the first two — the ones that actually drive live-birth rates. Reserve you cannot rebuild; quality you can meaningfully support.
Baseline evaluation — what to actually order
Before any 90-day protocol, get a real baseline. The core panel:
- AMH (any cycle day) — ovarian reserve snapshot. How to interpret AMH.
- Day-3 FSH, LH, estradiol — reserve and hypothalamic-pituitary function.
- TSH, free T4, TPO antibodies — subclinical hypothyroidism roughly doubles miscarriage risk; treat below 2.5 mIU/L in TTC.
- Vitamin D 25-OH — target 40–60 ng/mL; deficiency associates with lower IVF success and higher miscarriage.
- Ferritin, CBC, HbA1c, fasting insulin — metabolic and iron status. HOMA-IR > 2 warrants inositol and lifestyle work.
- Prolactin, progesterone (day 21) — ovulatory confirmation.
- Semen analysis for the partner — half of infertility is male-factor and is often missed until year two.
The 90-day optimization protocol
Both egg and sperm take ~90 days to mature from precursor cells. That defines the minimum runway for supplementation to affect the cohort you'll actually ovulate.
- Egg-quality stack: Ubiquinol CoQ10 200–400 mg AM with fat, myo-inositol 2 g twice daily (40:1 with d-chiro), alpha-lipoic acid 300 mg, omega-3 DHA 600 mg.
- Prenatal: 5-MTHF 800 mcg (methylated folate, not synthetic folic acid if MTHFR-variant), choline 450 mg, iron 18 mg if ferritin < 40, iodine 150 mcg, vitamin D 2000–4000 IU titrated to level.
- Partner: L-carnitine 2 g, zinc 30 mg, CoQ10 200 mg, selenium 100 mcg, ashwagandha KSM-66 600 mg. See male fertility supplements.
- Metabolic: Protein 1.2–1.6 g/kg, walk 8k steps daily, strength train 2–3×/week, sleep 7.5+ hours. Alcohol under 3 drinks/week (partner included).
- Timing: LH strips or wearable BBT; intercourse every 1–2 days from cycle day 10 through confirmed ovulation.
Contraindications and cautions
- Do not take GLP-1s (semaglutide, tirzepatide) while TTC or pregnant. Wash out at least 8 weeks before conception attempts per FDA labeling.
- Systemic HRT is contraindicated during TTC. Vaginal estrogen for GSM is generally compatible — confirm with clinician.
- Retinoids (isotretinoin, high-dose vitamin A >10,000 IU) are teratogenic. Stop before TTC.
- Untreated thyroid disease, uncontrolled diabetes, and BMI extremes all measurably reduce live-birth rates — address before or alongside protocols.
When to escalate to REI
Standard ASRM guidance:
- Age < 35: try 12 months before workup.
- Age 35–39: try 6 months before workup.
- Age 40+: workup at 3 months (or immediately if AMH < 1.0 or cycles are irregular).
- Any age with known endometriosis, PCOS, tubal disease, prior chemo/radiation, or two or more losses: workup now.
Request a fertility consult for triage and REI referral if warranted. Time-to-referral is the single largest modifiable factor in over-35 live-birth outcomes.
Sources
- Dunson DB, et al. Increased infertility with age in men and women. Obstet Gynecol 2004.
- Bentov Y, Casper RF. The aging oocyte — can mitochondrial function be improved? Fertil Steril 2013.
- Xu Y, et al. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality. Reprod Biol Endocrinol 2018.
- Practice Committee of ASRM. Optimizing natural fertility. Fertil Steril 2022.
Related
Frequently asked questions
When should I see a fertility specialist?
Standard guidance is after 6 months of unprotected intercourse if you are over 35, or sooner if cycles are irregular, you have known endometriosis/fibroids, or there is male-factor history.
Is AMH testing necessary?
Not mandatory, but useful. AMH gives a snapshot of ovarian reserve — not fertility per se. Pair with antral follicle count via ultrasound for a fuller picture.
How long before TTC should I optimize?
Plan for 90 days minimum. Both eggs and sperm take roughly 3 months to mature from precursor to ready-to-fertilize.
Do supplements actually help?
CoQ10, myo-inositol, methylated folate, and omega-3 DHA have the strongest evidence. They are adjuncts, not a substitute for clinical evaluation.
Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.
Request your Longevity Consult →Explore Kindr Health
Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service
Written and medically reviewed by the Kindr Health Clinical Team · Published 2026-06-19 · Last reviewed 2026-06-23. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.